Jake Kurtis, MD, PhD is on site at the #ASTMH24 conference in New Orleans this week, connecting with colleagues who are working to find a solution to the growing limitations of current malaria drug options. #discoveryscience https://lnkd.in/epuPgS3d
关于我们
Ocean Biomedical is a new-generation biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We're working to bring together the interdisciplinary expertise and resources required to develop a diverse portfolio of pharmaceutical inventions and technologies through preclinical, clinical, and commercial development. We aim to build a continuous pipeline of drug development opportunities through our relationships with universities and medical centers. Our current product candidates consist of preclinical programs each with potential for broad application in oncology, fibrosis, and the treatment and prevention of severe malaria. Our programs in oncology and fibrosis are based on discoveries of disease pathways and related drug targets emerging from pioneering work in the field of chitinase biology by our scientific co-founder, Jack A. Elias, M.D., a pulmonary specialist who was formerly the Dean of Medicine at Brown, and the Chairman of Medicine at Yale. In infectious disease, we are developing both therapeutic and vaccine candidates against malaria, a disease that kills 500,000 children and infects 200-300 million people globally each year. Our malaria program is built on the discovery by Jonathan Kurtis, M.D., of two novel malaria antigens, PfSEA-1 and PfGARP which have shown a significant reduction in malaria parasites under multiple levels of in-vitro and animal model testing. (press links below). Kurtis is the Chairman of Pathology and Laboratory Medicine at Brown and the founding director of the Center for International Health Research.
- 网站
-
https://www.oceanbiomedical.com
OCEAN BIOMEDICAL的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Providence，RI
- 类型
- 私人持股
- 创立
- 2019
- 领域
- biopharma、medicine、research、discovery、global medicine、drug development、malaria和fibrosis
地点
-
主要
获取路线
US，RI，Providence，02903
OCEAN BIOMEDICAL员工
-
Michael Peterson
Experienced CEO, CFO, Board Leader, and Growth Strategist | Driving Success in Oil & Gas, Capital Markets, and Business Growth
-
Robert (Bob) Sweeney
Ocean Biomedical, Inc. Chief Accounting Officer
-
Chirinjeev Kathuria
Investor, serial entrepreneur, physician, and philanthropist
-
Sharon Talcott
Ocean Biomedical, Inc. Vice President, Strategic Partnerships
动态
-
Artemisinin-resistant malaria is real and growing. New meds are needed now. https://lnkd.in/e2zvUdNT #malaria #discovery #science
-
Congratulations, Sue! Keep the brilliant science rolling...
Congratulations to our COO Sue Currie for joining the Executive Board of the Coalition for Global Hepatitis Elimination! We know Dr. Currie will bring her decades of experience to this amazing organization to help find treatment options and potential cures for the millions of patients worldwide living with hepatitis.
-
Congratulations to our Joint Venture Partner, Virion Therapeutics, on positive results from their First-in-human, First-in-class Novel Checkpoint Modifier for an HBV Functional Cure. Virion presented their findings today at #EASL2024 in Milan. Brilliant work! #biopharma #HBV #discovery #science $ocea
-
#InvestorsObserver says $OCEA was the top performing stock on the #Russell2000 in Q1 2024. ?????? ?? ?????? Lots to be done, but we will celebrate every good milestone along the way!
-
-
We have a lot of work to do before we become an #NVIDIA, but it is always nice to be mentioned in the same paragraph on a "Hot Stocks" list - we'll take it! #discoveryscience #biopharma #innovation #cancer #globalhealth $ocea https://lnkd.in/eP-VjJY8
-
Congratulations to our JV Partner Virion Therapeutics, LLC for their strong initial safety data on VRON-0200! We are excited for the next steps in this groundbreaking work towards an HBV functional cure. Highlights from today's presentation at APASL 2024 Kyoto include: ? Initial safety data presented on the first 10 chronically?HBV-infected patients representing 674 patient days of treatment. ? VRON-0200 was well tolerated, with no serious adverse events (SAEs) observed: no patients discontinued treatment; one treatment related adverse event was reported (flu-like symptoms which resolved without treatment) ? No other clinically relevant abnormalities in laboratory tests, including liver function tests, electrocardiograms (ECG), or vital signs were reported Immunologic assessments are ongoing, data expected to be submitted to an upcoming meeting
Today we presented our first ever human data for our lead program, VRON-0200 for HBV Functional Cure at the APASL meeting in Kyoto, Japan. These data, the first ever for a genetically encoded checkpoint modifier containing vaccine of any kind, represent a critical first step in Virion's mission to bring a safe, well tolerated, and easy to administer interferon-sparing functional cure immunotherapy to HBV-infected patients worldwide. We look forward to sharing additional safety, as well as immunologic and virologic data, later this year. The full presentation can be found at our website, www.VirionTx.com.